Profile: Jaguar Health Inc (JAGX.A)
12 Jul 2019
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., incorporated on June 6, 2013, is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy.
The Company’s Mytesi is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Its Canalevia is animal prescription drug candidate for treatment of various forms of diarrhea in dogs. It is also developing Equilevia, a non-prescription product for total gut health in equine athletes. The Company is developing Neonorm Calf and Neonorm Foal as non-prescription animal products.
Jaguar Health Inc
201 Mission St Ste 2375
SAN FRANCISCO CA 94105-1839